SRR33346952
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.420
- PANCREAS_BETA_CELLS+0.290
- CHOLESTEROL_HOMEOSTASIS+0.250
- TGF_BETA_SIGNALING+0.190
- UV_RESPONSE_DN+0.170
- SPERMATOGENESIS+0.150
- ANDROGEN_RESPONSE+0.120
- BILE_ACID_METABOLISM+0.110
- FATTY_ACID_METABOLISM+0.080
- HEME_METABOLISM+0.070
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- HEDGEHOG_SIGNALING-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- IL6_JAK_STAT3_SIGNALING-0.300
- NOTCH_SIGNALING-0.290
- G2M_CHECKPOINT-0.280
- TNFA_SIGNALING_VIA_NFKB-0.270
- INTERFERON_GAMMA_RESPONSE-0.240
- WNT_BETA_CATENIN_SIGNALING-0.230
- APICAL_JUNCTION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R141 | — | — | 0.812 |
| 2 | SRR10900594 | — | — | 0.761 |
| 3 | GSM6454733 | — | A | 0.755 |
| 4 | BS_ME3HKN2C | Ganglioglioma | — | 0.754 |
| 5 | MNG1173 | — | — | 0.748 |
| 6 | SRR1339387 | GTEX | — | 0.745 |
| 7 | 84a15687-a977-43a1-b2b7-099ecdf21b2c | — | — | 0.743 |
| 8 | SRR12202429 | — | — | 0.739 |
| 9 | SRR4296076 | — | cohortA1 | 0.737 |
| 10 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |